Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.55 |
| ▸ | BLM | P54132 | 1/20 | 0.45 |
| ▸ | PTPN1 | P18031 | 3/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.30 |
| ▸ | CDC25B | P30305 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL931358 | 0.98 | LMNA (0.59) | LMNABLMPTPN1MEN1CYP3A4 | |
| SCHEMBL7754183 | 0.98 | LMNA (0.59) | LMNABLMPTPN1MEN1CYP3A4 | |
| SCHEMBL8812227 | 0.81 | LMNA (0.39) | LMNABLM | |
| SCHEMBL8812570 | 0.81 | LMNA (0.39) | LMNABLM | |
| SCHEMBL1410326 | 0.80 | — | — | |
| SCHEMBL14778126 | 0.79 | LMNA (0.48) | LMNABLMPTPN1MEN1CYP3A4 | |
| SCHEMBL8384133 | 0.78 | — | — | |
| SCHEMBL14777945 | 0.78 | LMNA (0.59) | LMNABLMPTPN1MEN1CYP3A4 | |
| SCHEMBL1827120 | 0.78 | LMNA (0.59) | LMNABLMPTPN1MEN1CYP3A4 | |
| SCHEMBL14836402 | 0.78 | LMNA (0.40) | LMNABLMPTPN1MEN1CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 462 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3109254-B1 | CROSSLINKED NUCLEOSIDE AND NUCLEOTIDE | UNIV OSAKA (JP) | 2018-04-11 | — | — | EP | claimed |
| WO-2006106528-A1 | NOVEL PEPTIDES USEFUL FOR TREATMENT OF ALOPECIA | DABUR PHARMA LIMITED (IN) | 2006-10-12 | — | — | WO | claimed |
| US-6828304-B1 | Lipid-peptide conjugates containing fatty acids of different sizes, which inhibits the binding of Vasoactive intestinal peptide to its receptor | DABUR RESEARCH FOUNDATION (IN) | 2004-12-07 | — | — | US | claimed |
| EP-1409519-A1 | LIPID-PEPTIDE CONJUGATES FOR TREATMENT OF CANCER | Dabur Research Foundation (IN) | 2004-04-21 | — | — | EP | claimed |
| WO-2002010193-A1 | LIPID-PEPTIDE CONJUGATES FOR TREATMENT OF CANCER | DABUR RESEARCH FOUNDATION (IN) | 2002-02-07 | — | — | WO | claimed |
| WO-2024135721-A1 | METHOD FOR PRODUCING PRODUCTION INTERMEDIATE, PRODUCTION INTERMEDIATE THEREOF, AND METHOD FOR PRODUCING CROSSLINKED ARTIFICIAL NUCLEIC ACID INTERMEDIATE BY USING SAME | 田辺三菱製薬株式会社 | 2024-06-27 | — | — | WO | disclosed |
| WO-2024101446-A1 | MODIFIED NUCLEOSIDE HAVING GUANIDINO STRUCTURE IN BRIDGED PART AND METHOD FOR PRODUCING OLIGONUCLEOTIDE USING SAME | ルクサナバイオテク株式会社 | 2024-05-16 | — | — | WO | disclosed |
| CN-112513062-B | Oligonucleotide-containing small cell lung cancer therapeutic agent | 国立大学法人大阪大学 | 2024-05-10 | — | — | CN | disclosed |
| US-20240148775-A1 | OLIGONUCLEOTIDE FOR INDUCING N-EXON SKIPPING DURING REST MRNA PRECURSOR PROCESSING | OSAKA UNIVERSITY (JP) | 2024-05-09 | — | — | US | disclosed |
| CN-117964674-A | Bridged artificial nucleic acid ALNA | 田边三菱制药株式会社 | 2024-05-03 | — | — | CN | disclosed |
| CN-117964673-A | Bridged artificial nucleic acid ALNA | 田边三菱制药株式会社 | 2024-05-03 | — | — | CN | disclosed |
| US-11939421-B2 | Or relating to curing agents | HEXCEL COMPOSITES LIMITED (GB) | 2024-03-26 | — | — | US | disclosed |
| EP-0844000-A1 | Use of alpha, omega-diarylalkane derivatives in the treatment and prevention of psychosis | SANKYO COMPANY LIMITED (JP) | 1998-05-27 | — | — | EP | disclosed |
| EP-0795326-A1 | OCULAR TENSION DEPRESSANT | SANKYO COMPANY LIMITED (JP) | 1997-09-17 | — | — | EP | disclosed |
| CN-1157286-A | N,N-dimethyl-1-t-butoxycarbonyl-4-phenylpiperidine-4-carboxamide | SANKYO CO (JP) | 1997-08-20 | — | — | CN | disclosed |
| EP-0776893-A1 | Azaheterocyclic compounds having tachykinin receptor antagonist activity; Nk1 and NK2 | SANKYO COMPANY LIMITED (JP) | 1997-06-04 | — | — | EP | disclosed |
| EP-0468497-B1 | Peptide-antagonists of bombesin/GRP | MERRELL PHARMA INC (US) | 1997-05-28 | — | — | EP | disclosed |
| US-5556864-A | TREATMENT OF CIRCULATORY DISEASES AND PSYCHOSIS | SANKYO COMPANY, LIMITED (JP) | 1996-09-17 | — | — | US | disclosed |
| EP-0600717-A1 | Phenoxyalkylamines, -pyrrolidines and -piperidines for the treatment and prevention of circulatory diseases and psychosis | SANKYO COMPANY LIMITED (JP) | 1994-06-08 | — | — | EP | disclosed |
| EP-0468497-A2 | Peptide-antagonists of bombesin/GRP | MERRELL PHARMACEUTICALS INC. (US) | 1992-01-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240148775-A1 | OLIGONUCLEOTIDE FOR INDUCING N-EXON SKIPPING DURING REST MRNA PRECURSOR PROCESSING | UPF1, RBM17, NSUN2 | LMNA 385/4885BLM 1487/4885PTPN1 1369/4885 |
| US-11939421-B2 | Or relating to curing agents | FABP4, RARA, ADIPOR1 | LMNA 585/4885BLM 190/4885PTPN1 2663/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.